Relapse Cytogenetics Overview of ALLR3 genetics Introduction to the IntReALL trial. Anthony V Moorman Leukaemia Research Cytogenetics Group
|
|
- Maria Golden
- 5 years ago
- Views:
Transcription
1 Relapse Cytogenetics Overview of ALLR3 genetics Introduction to the IntReALL trial Anthony V Moorman Leukaemia Research Cytogenetics Group
2 Overview of ALLR3 Parker et al, Lancet 2010; 376:
3 Mitoxantrone better than Idarubicin Parker et al, Lancet 2010; 376:
4 ALL97/99: Cytogenetic Risk Groups Moorman et al (2010) Lancet Oncology, 11:
5 ALLR3 Cytogenetics at diagnosis and relapse Diagnosis Haploid 2% Relapse Haploid 3% t(5;14) 2% TAL1 2% Other 28% RUNX1 17% HeH 25% iamp21 5% IGH 1% TCR 2% t(5;14) 1% TAL1 2% Other 29% TCR 1% ETV6- ETV6- RUNX1 16% HeH 24% iamp21 5% IGH 1% Normal 10% t(17;19) 1% MLL 4% t(1;19) 2% Normal 9% MLL 5% t(1;19) 2% t(17;19) 1% High degree of stability between diagnosis and relapse for primary chromosomal abnormalities. Among 139 patients appropriately tested only 1 (0.7%) did not show the presence of the same abnormality at relapse.
6 Distribution of ALLR3 patients by cytogenetic risk group Patients with good risk cyto significantly younger (10.4y v 8.9y) Poor Risk, 67, 19% Intermedi ate Risk, 115, 33% ETV6- RUNX1, 66, 19% HeH, 99, 29% No strong relationship between cytogenetic risk group: Site of relapse; but patients with high risk cyto slightly more likely to have marrow involvement. 30% testes relapses were ETV6-RUNX1 MRD at day 35 but patients with high risk cyto slightly more likely to be MRD positive Based on 347 patients classified using either diagnostic or relapse karyotype
7 Cytogenetic risk group linked to time to relapse Late Early Very Early 20 0 ETV6-RUNX1 HeH Intermediate Risk Poor Risk
8 Multiplex Ligation-dependent Probe Amplification (SALSA MLPA kit P335-A1 ALL IKZF1) Probes for genes most frequently deleted in BCP-ALL IKZF1 (8) Early B-cell differentiation gene (deleted in 29% high risk ALL) CDKN2A/B (3) Cell cycle G1 control -CDK inhibitor and p53 stabilizer (deleted in 20% BCP-ALL) PAX5 (6) B-cell differentiation gene (deleted in 32% of BCP-ALL) EBF1 (4) - Early B-cell differentiation gene activating PAX5 ETV6 (6) Transcription factor required for haematopoiesis (involved in translocations in ALL and deleted in 5%) BTG1 (4) Negative regulator of cell cycle RB1 (5) - Negative regulator of cell cycle (deleted in 5-11% B-ALL) CRLF2/CSF2RA/IL3RA (1 each) Deregulated in 6% BCP-ALL
9 ALLR3 cohort available for MLPA testing 416 B-lineage cases 227 tested by MLPA 184 (44%) tested at relapse Representative wrt age, sex, time to relapse Tested slightly more cases with high risk cytogenetics and marrow involvement. 35 had isolated extramedullary relapses only one positive for any deletion 149 (36%) had marrow involvement 145 (35%) tested at diagnosis Representative wrt age, sex, cytogenetics Tested marginally more cases who went on to have isolated CNS relapses and had early relapse. 102 (25%) tested at both time-points. 78 with marrow involvement
10 Incidence of micro-deletions in BCP-ALL patients Original diagnosis (n=145) Marrow Relapse (n=149) Data from ALLR3
11 Incidence of micro-deletions in BCP-ALL patients 78 matched pairs only Percentage of cases with micro-deletion IKZF1 CDKN2A/B PAX5 RB1 BTG1 ETV6 EBF1 P2RY8-CRLF2 Percentage of cases with micro-deletion IKZF1 CDKN2A/B PAX5 RB1 BTG1 ETV6 EBF1 P2RY8-CRLF2 Original diagnosis Marrow Relapse Data from ALLR3
12 Genetic changes between diagnosis and relapse Losses, 10, 13% Mix, 6, 8% No change, 34, 46% Gains, 25, 33%
13 Incidence of micro-deletions by cytogenetic risk group IKZF1 CDKN2A/B 0 ETV6-RUNX1 HeH Intermediate Risk Poor Risk Overall
14 Incidence of micro-deletions by time to relapse IKZF1 CDKN2A/B Very early Early Late Overall Excluding good risk cytogenetics 50% of late relapses have an IKZF1 deletion
15
16 ALLR3 Cytogenetics - Summary Cytogenetic risk group predicts outcome post-relapse - among standard risk patients. Spectrum of micro-deletions similar at relapse compared to presentation. Gains and losses observed in matched pairs but gains more common. Incidence of IKZF1 and CDKN2A/B deletions increases at relapses. Preliminary analysis shows that there is no association between IKZF1 or CDKN2AB deletions and outcome post relapse among ALLR3 patients Future plans supplement cohort with ~30 UK cases and add 73 ANZCHOG cases
17 IntReALL 2010 consortium
18 Outline of treatment schedule of IntReALL 2010 Recruitment Target patients over 4 years BFM Relapse Arm ALLR3 Relapse Arm Under review
19 IntReALL Diagnostics & correlative science overview Relapse sample Diagnostics - Morphology - Immunophenotype - Genetics (cyto/mol) - MRD (PCR/Flow) National representative Central IntReALL Trial Database (Marvin) National Biobanking Xenograft bank Pop Gen Tech Targeted NGS Genomic annotation Clinical and Scientific Research Projects Central IntReALL Diagnostic, Biobanking & Research Database (Scopeland)
20 Cytogenetic Representatives Zuzana Zemanova Joelle Tchinda Oskar Haas Bertil Johansson Anthony Moorman Anna Poluha Valerie de Haas Marta Jeison / Batia Stark Helene Cave Hiroaki Goto Paula Gameiro Silivia Bungaro / Anna Leszl Rosemary Sutton / Tom Revesz
21 Guidelines for minimum standards & data Collect details of genetic testing performed at diagnosis/presentation and relapse Essential tests Full G/R-banded analysis (or SNP/CGH array) of all samples from marrow relapses. Targeted FISH / RT-PCR testing in all relapses for the principal genetic abnormality observed at diagnosis If no/failed diagnostic genetics then Screen relapse sample for all principal genetic abnormalities Recommended tests Screening for key secondary abnormalities Greatest variability across laboratories in terms of techniques and targets Should attempt to capture data that meets key standards
22 Guidelines for minimum standards & data Yes Was a PGA detected at initial diagnosis? No Perform cytogenetic analysis and test for that particular abnormality using an appropriate method. Yes Were all PGAs tested for appropriately at initial diagnosis? No Perform cytogenetic analysis. No more essential tests required. PGA Principal Genetic Abnormality Perform cytogenetic analysis. Test for any PGA that was not tested for at initial diagnosis.
23 Principal Genetic Abnormalities in BCP-ALL Abnormality t(12;21)(p13;q22) / ETV6-RUNX1 Detection Method FISH, RT-PCR t(1;19)(q23;p13) / TCF3-PBX1 MLL translocations* t(4;11)(q21;q23)/mll-af4; t(11;19)(q23;p13.3)/mll-enl etc t(9;22)(q34;q11.2) / BCR-ABL1 Cytogenetics FISH RT-PCR t(17;19)(q22;p13) / TCF3-HLF IGH@ translocations* IGH@-CRLF2, IGH@-CEBP, IGH@-ID4, etc Near haploidy (<30 chromosomes) Low hypodiploidy / near triploidy (30-39 / chromosomes) High hyperdiploidy (51-65 chromosomes) Intrachromosomal amplification of chromosome 21 (iamp21) FISH Cytogenetics, DNA index, Array CGH, SNP array, FISH (panel of centromeric probes) FISH with AML1/RUNX1 probe Array CGH, SNP array * In the case of MLL and IGH@ translocation it is not necessary to identify the partner gene.
24 Principal Genetic Abnormalities in T-ALL Abnormality TAL1 rearrangement* SIL-TAL1/del(1)(p32) TLX3 rearrangement* t(5;14)(q35;q32) / BCL11B-TLX3 t(5;14)(q35;q11) / TRA@/TRD@-TLX3 TLX1 rearrangement* t(10;14)(q24;q11) / TRA@/TRD@-TLX1 t(7;10)(q34~36;q24) / TRB@-TLX1 LMO2 rearrangement* t(11;14)(p13;q11) / TRA@/TRD@-LMO2 t(7;11)(q34~36;p13) / TRB@-LMO2 MLL translocations* t(11;19)(q23;p13.3)/mll-enl, etc HOXA translocations inv(7)(p15q34)/trb@-hoxa t(7;7)(p15;q34)/ TRB@-HOXA MYB translocations t(6;7)(q23;q34) CALM-AF10 / t(10;11)(p13;q14) Appropriate Test FISH RT-PCR Cytogenetics FISH RT-PCR * In the case of these rearrangements it is not necessary to identify the partner gene or promoter.
25 Guidelines for minimum standards & data Collect full details of genetic testing performed at diagnosis/presentation Essential tests Full G/R-banded analysis (or SNP/CGH array) of all samples from marrow relapses. Targeted FISH / RT-PCR testing in all relapses for the principal genetic abnormality observed at diagnosis If no/failed diagnostic genetics then Screen relapse sample for all principal genetic abnormalities Recommended tests Screening for key secondary abnormalities Greatest variability across laboratories in terms of techniques and targets. Should attempt to capture data that is comparable.
26 Recommended tests for secondary abnormalities BCP-ALL cases IKZF1 deletions MLPA P335 / P202 kit PCR assay / FISH CRLF2 abnormalities Genomic rearrangements only P2RY8-CRLF2 by MLPA (P335), FISH, RT-PCR BCP-ALL & T-ALL cases TP53 deletions/mutations by MLPA, FISH / PCR-Sequencing
27 Collection of Molecular Cytogenetic Data National representative Central IntReALL Trial Database (Marvin) Limited dataset of a few key variables from the relapse required for trial Research Data from PopGenTech, Genomics, etc. Central IntReALL Diagnostic, Biobanking & Research Database (Scopeland) Full genetic profile of both the diagnostic and relapse samples
28 Clinical and Scientific Research Questions Factors influencing the time to relapse Biology of extra medullary relapses (mouse model) Characterisation of rare genetic subtypes Genetics and biology of T-ALL Down Syndrome ALL Effect of primary therapy on type and curability of relapses Proteomics - RPPA Signalling pathways of different genetic subtypes
29 Acknowledgements UKCCG Laboratories DCOG Cytogenetic Laboratories ANZCHOG Cytogenetic Laboratories ALLR3 team especially Catriona Parker and Vaskar Saha IntReALL team especially Vaskar Saha, Julie Irving, Conny Eckert and Oskar Haas LRCG Amy Erhorn, Claire Schwab, Alannah Eliott, Stacey Richardson, Christine Harrison etc.
Celebrating 20 years of the Database Joint UKCCG and CHO Annual Conference. 22 nd -23 rd March 2012 Newcastle upon Tyne
Celebrating 20 years of the Database Joint UKCCG and CHO Annual Conference 22 nd -23 rd March 2012 Newcastle upon Tyne The following years. FISH and genomics Christine Harrison Chair, UK Cancer Cytogenetics
More information35 th UKCCG Meeting. Joint UKCCG and CHO Annual Conference. 9 th 10 th April 2013 Newcastle upon Tyne
35 th UKCCG Meeting Joint UKCCG and CHO Annual Conference 9 th 10 th April 2013 Newcastle upon Tyne Welcome! 35 th UKCCG Meeting Joint UK Cancer Cytogenetics Group and Centre Haemato-Oncology Annual Conference
More informationRisk Stratification in Childhood Leukemia
Risk Stratification in Childhood Leukemia Why is risk stratification important? Toxicities Deepa Bhojwani, MD May 11, 2018 To determine intensity of therapy - When to intensify therapy - When to de-intensify
More informationHD-SNP Microarray Analysis of the Study 9 High Risk ALL Patients -
HD-SNP Microarray Analysis of the Study 9 High Risk ALL Patients - Increased Yield of Important Prognostic Information Nadine K Berry 1,2,4, Rodney J. Scott 1,4, Rosemary Sutton 5, Toby N Trahair 5, Philip
More informationHandout for lecture on lymphoblastic neoplasms presented by Rob McKenna
Handout for lecture on lymphoblastic neoplasms presented by Rob McKenna The following slides represent a near final version of the presentation that will be given in Maui, January 23,2018. Minor changes
More informationCase 1. Sa A.Wang, MD UT MD Anderson Cancer Center Houston, TX
Case 1 Sa A.Wang, MD UT MD Anderson Cancer Center Houston, TX Disclosure of Relevant Financial Relationships The USCAP requires that anyone in a position to influence or control the content of all CME
More informationSALSA MLPA probemix P383-A1 T-ALL Lot A
SALSA MLPA probemix P383-A1 T-ALL Lot A1-0213. T-lineage acute lymphoblastic leukaemia (T-ALL) is a clonal malignant disorder of immature T-cells, which accounts for about 15% of paediatric and 25% of
More informationLLR Childhood Leukaemia CellBank Anne Thomson, CellBank Manager..org.uk
LLR Childhood Leukaemia CellBank Anne Thomson, CellBank Manager.org.uk Purpose To facilitate high quality translational research in childhood leukaemia: clinical and basic science Centralised specialist
More informationBCR ABL1 like ALL: molekuliniai mechanizmai ir klinikinė reikšmė. IKAROS delecija: molekulinė biologija, prognostinė reikšmė. ASH 2015 naujienos
BCR ABL1 like ALL: molekuliniai mechanizmai ir klinikinė reikšmė. IKAROS delecija: molekulinė biologija, prognostinė reikšmė. ASH 2015 naujienos Ph like ALL BCR ABL1 like acute lymphoblastic leukemia (ALL)
More informationADVANCES IN CHILDHOOD ACUTE LEUKEMIAS : GENERAL OVERVIEW
ADVANCES IN CHILDHOOD ACUTE LEUKEMIAS : GENERAL OVERVIEW Danièle SOMMELET European Scientific Seminar Luxemburg, 3.11.2009 1 Definition of acute leukemias Malignant process coming from lymphoid (85 %)
More informationCAALL-F01 OVERVIEW, OUTLINES COMITE LEUCEMIES 19 NOVEMBRE 2015
CAALL-F01 OVERVIEW, OUTLINES COMITE LEUCEMIES 19 NOVEMBRE 2015 Current outcomes in childhood and adolescent ALL: FRALLE 2000 protocol: 2176 pts; 1-20 years FRALLE Group Event-Free Overall Survival Survival
More informationTCF3 breakpoints of TCF3-PBX1 (patients 1a 5a) and TCF3-HLF (patients 6a 9a and11a) translocations.
Supplementary Figure 1 TCF3 breakpoints of TCF3-PBX1 (patients 1a 5a) and TCF3-HLF (patients 6a 9a and11a) translocations. The CpG motifs closest to the breakpoints are highlighted in red boxes and the
More informationLymphoblastic Leukemia / Lymphoma
1 5014 - Topics in Pediatric Hematopathology: Acute Lymphoblastic Leukemia, Including Changes in the Revised WHO Classification, and Unusual Pediatric Myeloid Neoplasms Robert W. McKenna, MD MASCP * Elizabeth
More informationtranslocations co-exist with other primary rearrangements in B-cell precursor acute lymphoblastic leukemia
Published Ahead of Print on May 9, 2014, as doi:10.3324/haematol.2014.103820. Copyright 2014 Ferrata Storti Foundation. IGH@ translocations co-exist with other primary rearrangements in B-cell precursor
More informationObjectives. Morphology and IHC. Flow and Cyto FISH. Testing for Heme Malignancies 3/20/2013
Molecular Markers in Hematologic Malignancy: Ways to locate the needle in the haystack. Objectives Review the types of testing for hematologic malignancies Understand rationale for molecular testing Marcie
More informationTest Name Results Units Bio. Ref. Interval. Positive
LL - LL-ROHINI (NATIONAL REFERENCE 135091534 Age 36 Years Gender Female 1/9/2017 120000AM 1/9/2017 105316AM 2/9/2017 104147AM Ref By Final LEUKEMIA GENETIC ROFILE ANY SIX MARKERS, CR QUALITATIVE AML ETO
More informationGenomic Characterization of Acute Leukemias
Review Received: November 3, 2013 Accepted: April 10, 2014 Published online: June 20, 2014 Genomic Characterization of Acute Leukemias Sabina Chiaretti Valentina Gianfelici Giulia Ceglie Robin Foà Division
More informationDr. Anjali Kelkar (DNB Path, IFCAP)
Acute Leukemias : Morphology and Beyond Dr. Anjali Kelkar (DNB Path, IFCAP) Consultant - Diagnostic Haematology NABL Assessor Senior Associate Professor, Incharge Haematology Labs Bharati Vidyapeeth Deemed
More informationRole of FISH in Hematological Cancers
Role of FISH in Hematological Cancers Thomas S.K. Wan PhD,FRCPath,FFSc(RCPA) Honorary Professor, Department of Pathology & Clinical Biochemistry, Queen Mary Hospital, University of Hong Kong. e-mail: wantsk@hku.hk
More informationPredicting relapse risk in childhood acute lymphoblastic leukaemia
review Predicting relapse risk in childhood acute lymphoblastic leukaemia David T. Teachey 1 and Stephen P. Hunger 2 1 Pediatric Hematology and Oncology, Children s Hospital of Philadelphia, University
More informationPRECURSOR LYMHPOID NEOPLASMS. B lymphoblastic leukaemia/lymphoma T lymphoblastic leukaemia/lymphoma
PRECURSOR LYMHPOID NEOPLASMS B lymphoblastic leukaemia/lymphoma T lymphoblastic leukaemia/lymphoma B lymphoblastic leukaemia/lymphoma Definition: B lymphoblastic leukaemia/lymphoma is a neoplasm of precursor
More informationOncology Genetics: Cytogenetics and FISH 17/09/2014
Oncology Genetics: Cytogenetics and FISH 17/09/2014 Chris Wragg Head of Oncology Genomics, BGL BGL Bristol Genetics Laboratory (BGL) CPA accredited Genetics laboratory serving a core population of 4-5million
More informationGENETICS OF HEMATOLOGICAL MALIGNANCIES
de DUVE INSTITUTE GENETICS OF HEMATOLOGICAL MALIGNANCIES INTERUNIVERSITY CERTIFICATE IN HUMAN GENETICS Université catholique de Louvain Brussels,19/02/2016 Professor Hélène Antoine-Poirel, MD, PhD Center
More informationValidation of the United Kingdom copy-number alteration classifier in 3239 children with B-cell precursor ALL
REGULAR ARTICLE Validation of the United Kingdom copy-number alteration classifier in 3239 children with B-cell precursor ALL Lina Hamadeh, 1, * Amir Enshaei, 1, * Claire Schwab, 1 Cristina N. Alonso,
More informationAcute leukemia and myelodysplastic syndromes
11/01/2012 Post-ASH meeting 1 Acute leukemia and myelodysplastic syndromes Peter Vandenberghe Centrum Menselijke Erfelijkheid & Afdeling Hematologie, UZ Leuven 11/01/2012 Post-ASH meeting 2 1. Acute myeloid
More informationTest Name Results Units Bio. Ref. Interval. Positive
LL - LL-ROHINI (NATIONAL REFERENCE 135091533 Age 28 Years Gender Male 1/9/2017 120000AM 1/9/2017 105415AM 4/9/2017 23858M Ref By Final LEUKEMIA DIAGNOSTIC COMREHENSIVE ROFILE, ANY 6 MARKERS t (1;19) (q23
More informationIDENTIFICATION AND EVALUATION OF NOVEL PROGNOSTIC GENETIC MARKERS FOR CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA
From the DEPARTMENT OF MOLECULAR MEDICINE AND SURGERY Karolinska Institutet, Stockholm, Sweden IDENTIFICATION AND EVALUATION OF NOVEL PROGNOSTIC GENETIC MARKERS FOR CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA
More informationBCR-ABL1-like cases in pediatric acute lymphoblastic leukemia: a comparison between DCOG/Erasmus MC and COG/St. Jude signatures
Published Ahead of Print on June 4, 2015, as doi:10.3324/haematol.2015.124941. Copyright 2015 Ferrata Storti Foundation. BCR-ABL1-like cases in pediatric acute lymphoblastic leukemia: a comparison between
More informationMolecular Markers. Marcie Riches, MD, MS Associate Professor University of North Carolina Scientific Director, Infection and Immune Reconstitution WC
Molecular Markers Marcie Riches, MD, MS Associate Professor University of North Carolina Scientific Director, Infection and Immune Reconstitution WC Overview Testing methods Rationale for molecular testing
More informationPh-like (BCR/ABL1-like): un apporoccio baato sul target molecolare
Ph-like (BCR/ABL1-like): un apporoccio baato sul target molecolare Sabina Chiaretti, MD PhD LE SFIDE DELLA MEDICINA DI PRECISIONE IN EMATOLOGIA Bologna 28 Giugno, 2018 Topics: BCR/ABL1-like and other subgroups
More informationApplication of Whole Genome Microarrays in Cancer: You should be doing this test!!
Application of Whole Genome Microarrays in Cancer: You should be doing this test!! Daynna Wolff, Ph.D. Director, Cytogenetics and Genomics Disclosures Clinical Laboratory Director and Employee, Medical
More informationAcute Lymphoblastic Leukemia in AYAs
Lugano, 11 May 2018 Acute Lymphoblastic Leukemia in AYAs Nicolas Boissel Hematology Department, AYA Unit Saint-Louis Hospital, Paris, France Discolures of commercial support Name of Company Research support
More informationReporting cytogenetics Can it make sense? Daniel Weisdorf MD University of Minnesota
Reporting cytogenetics Can it make sense? Daniel Weisdorf MD University of Minnesota Reporting cytogenetics What is it? Terminology Clinical value What details are important Diagnostic Tools for Leukemia
More informationInitial Diagnostic Workup of Acute Leukemia
Initial Diagnostic Workup of Acute Leukemia Guideline from the College of American Pathologists (CAP) and the American Society of Hematology (ASH) Publication: Archives of Pathology and Laboratory Medicine
More informationElisabeth Koller 3rd Medical Dept., Center for Hematology and Oncology, Hanusch Hospital, Vienna, Austria
Elisabeth Koller 3rd Medical Dept., Center for Hematology and Oncology, Hanusch Hospital, Vienna, Austria Incidence Diagnosis Prognostic factors Treatment Induction therapy - HSCT Indications for HSCT
More informationOncology Cytogenetics Diagnostic Service - User Guide 2014
Oncology Cytogenetics Diagnostic Service - User Guide 2014 Contact details Address: Cytogenetics Department 5 th Floor Tower Wing Guy s Hospital Great Maze Pond London SE1 9RT General enquiries 0207 188
More informationKrishna Reddy CH and Ashwin Dalal. Diagnostics Division, Centre for DNA Fingerprinting and Diagnostics, Hyderabad
Clinical Cytogenetics in the Diagnosis and Prognosis of Leukemias Krishna Reddy CH and Ashwin Dalal Diagnostics Division, Centre for DNA Fingerprinting and Diagnostics, Hyderabad Email: krishnareddy.chr@gmail.com
More informationIdentifying therapeutic targets by elucidating signaling pathways in pediatric lymphoid leukemias van der Sligte, Naomi Eline
University of Groningen Identifying therapeutic targets by elucidating signaling pathways in pediatric lymphoid leukemias van der Sligte, Naomi Eline IMPORTANT NOTE: You are advised to consult the publisher's
More informationChristine J Harrison, Oskar A Haas, W Harbott, Andrea Biondi, Martin Stanulla, Jan Trka, Shai Izraeli
Detection of prognostically relevant genetic abnormalities in childhood B-cell precursor acute lymphoblastic leukaemia: recommendations from the Biology and Diagnosis Committee of ibfm-sg Christine J Harrison,
More informationMolecular genetics of B-precursor acute lymphoblastic leukemia
Review series Molecular genetics of B-precursor acute lymphoblastic leukemia Charles G. Mullighan Department of Pathology, St. Jude Children s Research Hospital, Memphis, Tennessee, USA. B-precursor acute
More informationPhiladelphia-like B-cell precursor acute lymphoblastic leukemia (Ph-like
ARTICLE Acute Lymphoblastic Leukemia EUROPEAN HEMATOLOGY ASSOCIATION Ferrata Storti Foundation Adults with Philadelphia chromosome like acute lymphoblastic leukemia frequently have IGH-CRLF2 and JAK2 mutations,
More informationMolecular Markers in Acute Leukemia. Dr Muhd Zanapiah Zakaria Hospital Ampang
Molecular Markers in Acute Leukemia Dr Muhd Zanapiah Zakaria Hospital Ampang Molecular Markers Useful at diagnosis Classify groups and prognosis Development of more specific therapies Application of risk-adjusted
More informationCitation for published version (APA): Olsson, L. (2014). IKAROS and LEUKEMIA Division of Clinical Genetics, Lund University
IKAROS and LEUKEMIA OLSSON, LINDA Published: 2014-01-01 Link to publication Citation for published version (APA): Olsson, L. (2014). IKAROS and LEUKEMIA Division of Clinical Genetics, Lund University General
More informationMolecular Genetics of Paediatric Tumours. Gino Somers MBBS, BMedSci, PhD, FRCPA Pathologist-in-Chief Hospital for Sick Children, Toronto, ON, CANADA
Molecular Genetics of Paediatric Tumours Gino Somers MBBS, BMedSci, PhD, FRCPA Pathologist-in-Chief Hospital for Sick Children, Toronto, ON, CANADA Financial Disclosure NanoString - conference costs for
More informationControversies in Hematology: Case-Based Discussion. Acute leukemia in Adolescents and Young adults October 2018, Chiang Mai Thailand
Controversies in Hematology: Case-Based Discussion Acute leukemia in Adolescents and Young adults 25-26 October 2018, Chiang Mai Thailand Associate Prof. Adisak Tantiworawit, MD Division of Hematology,
More informationFluorescence in-situ Hybridization (FISH) ETO(RUNX1T1)/AML1(RUNX1) or t(8;21)(q21.3;q22)
PML/RARA t(15;17) Translocation Assay Result : nuc ish(pml 2)(RARA 2)[200] : 200/200(100%) interphase nuclei show normal 2O 2G signals for PML/RARA : is Negative for t(15;17)(q22;q21.1) 2 Orange 2 Green
More informationCarlos A Tirado *, David Shabsovich, Lei Yeh, Sheeja T Pullarkat, Lynn Yang, Michael Kallen and Nagesh Rao
Tirado et al. Biomarker Research (2015) 3:4 DOI 10.1186/s40364-015-0029-0 SHORT REPORT Open Access A (1;19) translocation involving TCF3-PBX1 fusion within the context of a hyperdiploid karyotype in adult
More informationOriginal article Korean J Pediatr 2013;56(6): Introduction
Original article Korean J Pediatr 2013;56(6):247-253 pissn 1738-1061 eissn 2092-7258 Korean J Pediatr Utility of a multiplex reverse transcriptasepoly merase chain reaction assay (HemaVision) in the evaluation
More informationJordi Esteve Hospital Clínic (Barcelona) Acute Leukemia Working Party. The European Group for Blood and Marrow Transplantation
36th EBMT & 9th Data Management Group Annual Meeting Vienna, 23 March 2010 Jordi Esteve Hospital Clínic (Barcelona) Acute Leukemia Working Party The European Group for Blood and Marrow Transplantation
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Mullighan CG, Su X, Zhang J, et al. Deletion of IKZF1 and prognosis
More informationMixed Phenotype Acute Leukemias
Mixed Phenotype Acute Leukemias CHEN GAO; AMY M. SANDS; JIANLAN SUN NORTH AMERICAN JOURNAL OF MEDICINE AND SCIENCE APR 2012 VOL 5 NO.2 INTRODUCTION Most cases of acute leukemia can be classified based
More informationChanges to the Hematopoietic and Lymphoid Neoplasm Coding Manual
Changes to the Hematopoietic and Lymphoid Neoplasm Coding Manual KCR 2018 SPRING TRAINING 2018 Hematopoietic Database Updates Updates were done to the Hematopoietic Database based on the WHO Hematopoietic
More informationMolecular Advances in Hematopathology
Molecular Advances in Hematopathology HOW MOLECULAR METHODS HAVE CHANGED MY PRACTICE Objectives Understand the importance of cytogenetic/molecular studies in hematolymphoid diseases Know some of the important
More informationTest Name Results Units Bio. Ref. Interval. Positive
Lab No 135091548 Age 35 Years Gender Female 1/9/2017 120000AM 1/9/2017 103420AM 4/9/2017 23753M Ref By Dr UNKNWON Final Test Results Units Bio Ref Interval LEUKEMIA DIAGNOSTIC COMREHENSIVE ROFILE 3 t (1;19)
More informationIntegrated genetic and epigenetic analysis of childhood acute lymphoblastic leukemia
Integrated genetic and epigenetic analysis of childhood acute lymphoblastic leukemia Maria E. Figueroa,, Ari Melnick, Charles G. Mullighan J Clin Invest. 2013;123(7):3099-3111. https://doi.org/10.1172/jci66203.
More informationManchester Cancer Haematological-Oncology Pathway Board. Guidelines for the Diagnosis and treatment of Adult Acute Lymphoblastic Leukaemia
Manchester Cancer Haematological-Oncology Pathway Board Guidelines for the Diagnosis and treatment of Adult Acute Lymphoblastic Leukaemia Coordinating author: Dr Anna Castleton Date of issue: June 2016
More informationPAX5-JAK2 fusion in acute lymphoblastic leukaemia. Dr Andrew Baldi Royal Children s Hospital 24 February 2017 Melbourne
PAX5-JAK2 fusion in acute lymphoblastic leukaemia Dr Andrew Baldi Royal Children s Hospital 24 February 2017 Melbourne Case 12-year-old girl Diagnosed with BCP ALL in November 2015 Presenting WCC 35x10
More informationHSCT - Minimum Essential Data - A REGISTRATION - DAY 0
HSCT - Minimum Essential Data - A REGISTRATION - DAY 0 Centre Identification EBMT Code (CIC): Contact person: Hospital: Email: Unit: Patient Data Date of this report: First transplant for this patient?:
More informationSupplementary Figure 1. Gating strategy for leukemic blasts and normal developing B
Supplementary Information Supplementary Figure 1. Gating strategy for leukemic blasts and normal developing B cells. (a) Gating strategy for lineage-negative blasts (B + Lin - cells), the starting population
More informationTherapy-related MDS/AML with KMT2A (MLL) Rearrangement Following Therapy for APL Case 0328
Therapy-related MDS/AML with KMT2A (MLL) Rearrangement Following Therapy for APL Case 0328 Kenneth N. Holder, Leslie J. Greebon, Gopalrao Velagaleti, Hongxin Fan, Russell A. Higgins Initial Case: Clinical
More informationNew Challenges in Targeting Signaling Pathways in Acute Lymphoblastic Leukemia by NGS Approaches: An Update
Review New Challenges in Targeting Signaling Pathways in Acute Lymphoblastic Leukemia by NGS Approaches: An Update Adrián Montaño 1,, Maribel Forero-Castro 2,, Darnel Marchena-Mendoza 1,2, Rocío Benito
More informationAcute leukemia & agressive lymphoma in children
Acute leukemia & agressive lymphoma in children Barbara De Moerloose Dept. Pediatric Hematology-Oncology and Stem Cell Transplantation Ghent University Hospital barbara.demoerloose@uzgent.be * Childhood
More informationIntegration of microarray analysis into the clinical diagnosis of hematological malignancies: How much can we improve cytogenetic testing?
/, Vol. 6, No. 22 Integration of microarray analysis into the clinical diagnosis of hematological malignancies: How much can we improve cytogenetic testing? Jess F. Peterson 1,2,6, Nidhi Aggarwal 3, Clayton
More informationThe Revised 2016 WHO Classification of Acute Leukemias
The Revised 2016 WHO Classification of Acute Leukemias Robert P Hasserjian, MD Associate Professor Massachusetts General Hospital and Harvard Medical School Acute leukemias Aggressive hematopoietic neoplasms
More informationCytogenetics Update. Lynda J Campbell
Cytogenetics Update Lynda J Campbell lynda.campbell@svhm.org.au Nowell and Hungerford, 1960 Ph Janet Rowley showed the Ph chromosome to be a balanced rearrangement: t(9;22) 9 22 Acute lymphoblastic leukaemia
More informationAcute Lymphoblastic Leukemia in Childhood
Acute Lymphoblastic Leukemia in Childhood Marie-Françoise Dresse Hemato-oncology Paediatric Unit Citadelle Hospital University of Liege -ULg EORTC Children Leukemia Group 1 Introduction Acute lymphoblastic
More informationStructure and Function of Fusion Gene Products in. Childhood Acute Leukemia
Structure and Function of Fusion Gene Products in Childhood Acute Leukemia Chromosomal Translocations Chr. 12 Chr. 21 der(12) der(21) A.T. Look, Science 278 (1997) Distribution Childhood ALL TEL-AML1 t(12;21)
More informationA pediatric patient with acute leukemia of ambiguous lineage with a NUP98-NSD1 rearrangement SH
A pediatric patient with acute leukemia of ambiguous lineage with a NUP98NSD1 rearrangement SH20170203 Rebecca LeemanNeill, Ronald Rice, Anita Malek, Patricia Raciti, Susan Hsiao, Mahesh Mansukhani, Bachir
More informationThe role of cytogenomics in the diagnostic work-up of Chronic Lymphocytic Leukaemia
The role of cytogenomics in the diagnostic work-up of Chronic Lymphocytic Leukaemia Adrian Zordan, Meaghan Wall, Ruth MacKinnon, Pina D Achille & Lynda Campbell Victorian Cancer Cytogenetics Service (VCCS)
More informationAddressing the challenges of genomic characterization of hematologic malignancies using microarrays
Addressing the challenges of genomic characterization of hematologic malignancies using microarrays Sarah South, PhD, FACMG Medical Director, ARUP Laboratories Department of Pediatrics and Pathology University
More informationClinical Guidelines for Lymphoid Diseases Acute Lymphoblastic Leukaemia (ALL)
Clinical Guidelines for Lymphoid Diseases Acute Lymphoblastic Leukaemia (ALL) Reference Number Version Status Executive Lead(s) Name and Job Title Author(s) Name and Job Title 13-2H-107 8 Dr Helen Barker
More informationStandard risk ALL (and its exceptions
Mahshid Mehdizadeh Standard risk ALL (and its exceptions WBC at diagnosis below 50 109/L - age 1 year - no central nervous system (CNS) involvement - ETV6/RUNX1 positivity - MRD at Day
More informationBlastic Plasmacytoid Dendritic Cell Neoplasm with DNMT3A and TET2 mutations (SH )
Blastic Plasmacytoid Dendritic Cell Neoplasm with DNMT3A and TET2 mutations (SH2017-0314) Habibe Kurt, Joseph D. Khoury, Carlos E. Bueso-Ramos, Jeffrey L. Jorgensen, Guilin Tang, L. Jeffrey Medeiros, and
More informationIntroduction to Cytogenetics
Introduction to Cytogenetics Catherine McCarthy Pathology Qld Cytogenetic abnormalities constitutional acquired: clonal: related or unrelated non-clonal Investigating constitutional abnormalities peripheral
More informationCase Report RCSD1-ABL1 Translocation Associated with IKZF1 Gene Deletion in B-Cell Acute Lymphoblastic Leukemia
Case Reports in Hematology Volume 2015, Article ID 353247, 6 pages http://dx.doi.org/10.1155/2015/353247 Case Report RCSD1-ABL1 Translocation Associated with IKZF1 Gene Deletion in B-Cell Acute Lymphoblastic
More informationFunctional characterization and targeting of CRLF2 gene alerations in pediatric High Risk Acute Lymphoblastic Leukemia
PhD Program in Molecular and Translational Medicine DIMET (XXVII cycle, year 2013-2014) University of Milano-Bicocca Department of Biotechnologies and Biosciences Functional characterization and targeting
More informationAcute Myeloid Leukemia with Recurrent Cytogenetic Abnormalities
Acute Myeloid Leukemia with Recurrent Cytogenetic Abnormalities Acute Myeloid Leukemia with recurrent cytogenetic Abnormalities -t(8;21)(q22;q22)(aml/eto) -inv(16) or t(16;16) -t(15;17) -11q23 Acute Myeloid
More informationRNA-SEQUENCING ANALYSIS IN B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA REVEALS ABERRANT GENE EXPRESSION AND SPLICING ALTERATIONS. A Thesis.
RNA-SEQUENCING ANALYSIS IN B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA REVEALS ABERRANT GENE EXPRESSION AND SPLICING ALTERATIONS A Thesis presented to the Faculty of the Graduate School at the University of Missouri-Columbia
More informationGENETIC MARKERS IN LYMPHOMA a practical overview. P. Heimann Dpt of Medical Genetics Erasme Hospital - Bordet Institute
GENETIC MARKERS IN LYMPHOMA a practical overview P. Heimann Dpt of Medical Genetics Erasme Hospital - Bordet Institute B and T cell monoclonalities Rearrangement of immunoglobin and TCR genes may help
More informationJ Clin Oncol 26: by American Society of Clinical Oncology INTRODUCTION
V O L U M E 2 6 N U M B E R 1 8 J U N E 2 0 2 0 0 8 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Minimal Residual Disease Values Discriminate Between Low and High Relapse Risk in Children With
More informationIntroduction CLINICAL TRIALS AND OBSERVATIONS
CLINICAL TRIALS AND OBSERVATIONS Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council
More informationApplication. Application of molecular biology methods in hematology and oncology. Oncogenes are involved in:
Application Application of molecular biology methods in hematology and oncology Research on the etiology of cancer Diagnostics / Differential diagnostics Stratifying for treatment Prognosing the outcome
More informationA population-based cytogenetic study of adults with acute lymphoblastic leukemia
From www.bloodjournal.org by guest on November 6, 2014. For personal use only. 2010 115: 206-214 doi:10.1182/blood-2009-07-232124 originally published online November 6, 2009 A population-based cytogenetic
More informationUse of MYC, BCL2 and BCL6 FISH for investigations of high grade B cell lymphoma
Use of MYC, BCL2 and BCL6 FISH for investigations of high grade B cell lymphoma Dr Anthony Bench Haematopathology and Oncology Diagnostic Service Cambrıdge Unıversıty Hospitals NHS Foundatıon Trust Cambridge
More informationRESEARCH ARTICLE. Prerana Bhandari 1, Firoz Ahmad 1, Rupa Dalvi 2, Neeraja Koppaka 2, Prajakta Kokate 2, Bibhu Ranjan Das 1, Swarna Mandava 2 *
DOI:http://dx.doi.org/10.7314/APJCP.2015.16.16.7219 RESEARCH ARTICLE Cytogenetic Profile of De Novo B lineage Acute Lymphoblastic Leukemia: Determination of Frequency, Distribution Pattern and Identification
More informationCLL Complete SM Report
Reported: 02/01/2012 Σ CGI ID No:5 Client:r Client Address: CLINICAL DATA: Lymphoma No CBC results provided. CLL Complete SM Report FINAL DIAGNOSIS: CD19+ B cell lymphoma, ZAP-70 + (44%), with borderline
More informationFuture Directions in Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia
Future Directions in Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia Heidi Trinkman, PharmD. Clinical Pharmacy Specialist Cook Children s Medical Center Fort Worth, Texas Disclosures Speaker s
More informationCase #16: Diagnosis. T-Lymphoblastic lymphoma. But wait, there s more... A few weeks later the cytogenetics came back...
Case #16: Diagnosis T-Lymphoblastic lymphoma But wait, there s more... A few weeks later the cytogenetics came back... 46,XY t(8;13)(p12;q12)[12] Image courtesy of Dr. Xinyan Lu Further Studies RT-PCR
More informationCLINICAL UTILITY OF INTEGRATED GENOMIC PROFILING IN PEDIATRIC LEUKEMIA
CLINICAL UTILITY OF INTEGRATED GENOMIC PROFILING IN PEDIATRIC LEUKEMIA FUMIN LIN, Ph.D. LINF1@EMAIL.CHOP.EDU CANCER GENOMIC DIAGNOSTIC LABORATORY DIVISION OF GENOMIC DIAGNOSTICS 1 PEDIATRIC LEUKEMIA Common
More informationMolecular Diagnosis. Nucleic acid based testing in Oncology
Molecular Diagnosis Nucleic acid based testing in Oncology Objectives Describe uses of NAT in Oncology Diagnosis, Prediction, monitoring. Genetics Screening, presymptomatic testing, diagnostic testing,
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Schlenk RF, Döhner K, Krauter J, et al. Mutations and treatment
More informationLoss of chromosomes is the primary event in near-haploid and low hypodiploid acute lymphoblastic leukemia.
Loss of chromosomes is the primary event in near-haploid and low hypodiploid acute lymphoblastic leukemia. Safavi, Setareh; Forestier, E; Golovleva, I; Barbany, G; Hansén Nord, Karolin; Moorman, A V; Harrison,
More informationWest Midlands Regional Genetics Laboratory
West Midlands Regional Genetics Laboratory Haemato-oncology service update letter October 2017 Dear colleagues, We are writing to outline the latest developments to our service, aiming to support the management
More informationNucleic Acid Testing - Oncology. Molecular Diagnosis. Gain/Loss of Nucleic Acid. Objectives. MYCN and Neuroblastoma. Molecular Diagnosis
Nucleic Acid Testing - Oncology Molecular Diagnosis Nucleic acid based testing in Oncology Gross alterations in DNA content of tumors (ploidy) Gain/Loss of nucleic acids Markers of Clonality Oncogene/Tumor
More informationAnalysis of Massively Parallel Sequencing Data Application of Illumina Sequencing to the Genetics of Human Cancers
Analysis of Massively Parallel Sequencing Data Application of Illumina Sequencing to the Genetics of Human Cancers Gordon Blackshields Senior Bioinformatician Source BioScience 1 To Cancer Genetics Studies
More informationChanges to the Hematopoietic and Lymphoid Neoplasm Coding Manual
Changes to the Hematopoietic and Lymphoid Neoplasm Coding Manual KCR 2018 SPRING TRAINING 2018 Hematopoietic Database Updates Updates were done to the Hematopoietic Database based on the WHO Hematopoietic
More informationDisclosures. An update on ancillary techniques in the diagnosis of soft tissue tumors. Ancillary techniques. Introduction
Disclosures An update on ancillary techniques in the diagnosis of soft tissue tumors. I have nothing to disclose. Andrew Horvai, MD, PhD Clinical Professor, Pathology Introduction Ancillary techniques
More informationVolume 7, Issue 1 January 2012
The Hong Kong College of Pathologists, Incorporated in Hong Kong with Limited Liability Volume 7, Issue 1 January 2012 Editorial note: Chronic lymphocytic leukaemia (CLL) is the commonest chronic lymphoproliferative
More informationMRD in ALL: Correct interpretation in clinical practice. Deepak Bansal Prof., Pediatric Hematology-Oncology unit PGIMER, Chandigarh
MRD in ALL: Correct interpretation in clinical practice Deepak Bansal Prof., Pediatric Hematology-Oncology unit PGIMER, Chandigarh Minimal residual disease Subclinical level of residual leukemia Below
More information